{
  "id": "mcrc-egfr-main",
  "display_name": "mCRC RAS/BRAF WT (Main)",
  "cohort": "Metastatic Colorectal Cancer, RAS/BRAF Wild Type, Q1 2023",
  "insight_type": "Treatment Patterns by Regimen",
  "summary": "EGFR inhibitor utilization is at 65% for eligible patients with RAS/BRAF wild type mCRC, below NCCN guidelines recommendation of 80%.",
  "recommendation": "Increase appropriate utilization of EGFR inhibitors in RAS/BRAF wild type mCRC patients.",
  "financial_impact": {
    "annual_opportunity": "$250,000/year",
    "math": "Optimizing EGFR inhibitor use could improve outcomes and generate approximately $250,000 in annual savings through improved progression-free survival."
  },
  "financial_impact_description": "Optimizing EGFR inhibitor use could improve outcomes and generate approximately $250,000 in annual savings through improved progression-free survival.",
  "peer_financial_impact": 320000,
  "peer_financial_impact_description": "Your organization trails peer benchmarks, with a potential financial opportunity of $320,000 annually.",
  "action_steps": [
    {
      "text": "Review molecular testing protocols to ensure all eligible patients receive RAS/BRAF testing",
      "icon": "chart-bar"
    },
    {
      "text": "Implement clinical decision support alerts for eligible patients",
      "icon": "user-group"
    },
    {
      "text": "Conduct provider education on NCCN guidelines for mCRC",
      "icon": "star"
    }
  ],
  "peer_action_steps": [
    "Benchmark against top-performing organizations",
    "Implement a targeted improvement plan",
    "Monitor both testing rates and appropriate EGFR inhibitor use"
  ],
  "chart_data": {
    "categories": [
      "Cetuximab",
      "Panitumumab",
      "Bevacizumab",
      "No biologic",
      "Other"
    ],
    "values": [
      40,
      25,
      20,
      10,
      5
    ],
    "peer_values": [
      50,
      30,
      15,
      3,
      2
    ],
    "target_values": [
      55,
      25,
      15,
      5,
      0
    ]
  },
  "drilldowns": [],
  "chart": {
    "type": "bar",
    "unit": "provider",
    "data": [
      {
        "name": "Cetuximab",
        "value": 40,
        "gap": 0,
        "highlight": true
      },
      {
        "name": "Panitumumab",
        "value": 25,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Bevacizumab",
        "value": 20,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "No biologic",
        "value": 10,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Other",
        "value": 5,
        "gap": 0,
        "highlight": false
      }
    ],
    "benchmark": 65,
    "nccn_target": 65
  },
  "clinical_impact": {
    "description": "Clinical impact analysis based on outcomes data and peer-reviewed literature.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+3.2 months",
        "description": "Potential median progression-free survival improvement"
      },
      {
        "type": "OS",
        "value": "+5.1 months",
        "description": "Potential median overall survival improvement"
      },
      {
        "type": "QoL",
        "value": "+15%",
        "description": "Enhanced quality of life measures"
      }
    ],
    "quantitative": "+5.1 months OS"
  },
  "weighted_score": 81
}